Breakthrough pain was initially managed by Dilaudid and then later changed to morphine sulfate.
The patient's requirement for breakthrough pain was more than three times per day.
The patient will also need to be continued on Keppra for the purpose of seizure prophylaxis.
Additionally, she experienced mild thrombocytopenia with a platelet count of 144; which, by the day of discharge, had increased to 156.
It was felt this could be secondary to Bactrim which she had been on for Pneumocystis carinii pneumonia prophylaxis.
